\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
^{^{[1]<\/sup><\/sup> Banerjee D, Wang AY. Personalizing heart failure management in chronic kidney disease patients. Nephrol Dial Transplant<\/i>. 2021;doi:10.1093\/ndt\/gfab026.<\/span><\/p> <\/td> \n <\/tr> \n}}
^{[2]<\/sup> Andersen MJ, Borlaug BA. Heart failure with preserved ejection fraction: current understandings and challenges. Curr Cardiol Rep<\/i>. 2014;16(7):501.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[3]<\/sup> GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet.<\/i> 2018;392(10159):1789–858.<\/span><\/p> <\/td> \n <\/tr> \n}
^{^{[4]<\/sup> <\/sup>ClinicalTrials.gov. EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04509674<\/a>. Accessed: October 2021.<\/span><\/p> <\/td> \n <\/tr> \n}}
^{^{[5]<\/sup> <\/sup>ClinicalTrials.gov. EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin). Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03594110<\/a>. Accessed: October 2021.<\/span><\/p> <\/td> \n <\/tr> \n}}
^{^{[6]<\/sup> <\/sup>GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet<\/i>. 2016; 388(10053):1459–544.<\/span><\/p> <\/td> \n <\/tr> \n}}
^{^{[7]<\/sup><\/sup> American Heart Association. Types of Heart Failure. Available at: https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/what-is-heart-failure\/types-of-heart-failure<\/a>. Accessed: September 2021.<\/span><\/p> <\/td> \n <\/tr> \n}}
^{^{[8]<\/sup><\/sup> Kenny HC, Abel ED. Heart Failure in Type 2 Diabetes Mellitus. Circ Res. <\/i>2019;124(1):121–41.<\/span><\/p> <\/td> \n <\/tr> \n}}
^{^{[9]<\/sup><\/sup> Calvert MJ, Freemantle N, Cleland JGF. The impact of chronic heart failure on health‐related quality of life data acquired in the baseline phase of the CARE‐HF study. Eur J Heart Fail<\/i>. 2005;7(2):243–51.<\/span><\/p> <\/td> \n <\/tr> \n}}
^{^{[10]<\/sup><\/sup> García-Donaire JA, Ruilope LM. Cardiovascular and Renal Links along the Cardiorenal Continuum. Int J Nephrol<\/i>. 2011;2011:975782.<\/span><\/p> <\/td> \n <\/tr> \n}}
^{^{[11]<\/sup><\/sup> Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes<\/i>. 2015;6(13):1246–58.<\/span><\/p> <\/td> \n <\/tr> \n}}
^{^{[12]<\/sup> <\/sup>Thomas M, Cooper M, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. <\/i>2015;12:73–81.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n}}
<\/p>"]; $("#dvExtra").html(content_array[0]);})();